AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01284309
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT00364390
Drug: Anginera, a human tissue replacement therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03305809
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT03872388
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients not eligible to receive atorvastatin in group II will be enrolled into non-statin observation group with/without capecitabine treatment. Capecitabine administration will be dosed as per standard of care. Standard of care dosing of Capecitabine is a 21 day cycle consisting 14 days on and 7 days off. The starting dosing will be per physician discretion, but may be up to 2500mg/m2 per day.
Trial: NCT01176318
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo capsule, twice daily for 10 days
Trial: NCT04014790
Drug: RGI-2001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive 6 weekly doses of RGI 2001, 100 μg/kg via IV administration after completion of alloHSCT
Trial: NCT04014790
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care prophylaxis regimen will be administered according to institutional guidelines
Trial: NCT00816556
Drug: Estriol
RxNorm normalized name: Estriol
DrugBank: Estriol (DB04573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estriol 10 micrograms added to Vanicream Lite 0.5 grams applied to vaginal introitus daily for 2 weeks and then twice weekly for 10 weeks.
Trial: NCT01057251
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg or 20 mg once daily, oral administration
Trial: NCT02509312
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in the experimental arm will receive ketorolac 30 mg in 1 ml at the time of cord clamp and then for 3 more doses every 6 hours.
Trial: NCT02509312
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the control arm will receive normal saline 1 ml at the time of cord clamp and then for 3 more doses every 6 hours.
Trial: NCT03927690
Drug: LKA651
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LKA651 5 mg Intravitreal injection, every 4 weeks for 12 weeks in the treatment phase
Trial: NCT00511277
Drug: Seroquel®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dosage form: oral, dosage: 300-800mg/d, frequency: twice daily
Trial: NCT01772823
Drug: Emtricitabine/tenofovir (FTC/TDF (Truvada®))
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects will be provided with daily FTC/TDF (Truvada®) as Pre-exposure prophylaxis (PrEP) for 48 weeks.
Trial: NCT00805285
Drug: Combination Oral Budesonide and Rectal Hydrocortisone
RxNorm normalized name: budesonide Rectal Foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 9 mg PO (oral) daily and hydrocortisone 100 mL PR (enema) for an 8-week period. The doses of each drug to be used in the pilot study are standard doses used in clinical practice. After 8-weeks, the budesonide will be tapered in the following manner: 1) budesonide 6 mg PO daily and hydrocortisone 100 ml PR every other day (EOD) for 3 weeks then 2) budesonide 3 mg PO daily and hydrocortisone 100 ml PR 2 x per week for 3 weeks then 3) discontinue budesonide.
Trial: NCT01117129
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. infusion on day 1 and 15
Trial: NCT01117129
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10-25 mg weekly
Trial: NCT01840449
Drug: Somatuline Autogel® 60, 90 or 120 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01289041
Drug: BKM120
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02209610
Drug: Intrathecal Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mu-opioid receptor agonist
Trial: NCT00551135
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00478322
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo of 100 mg BID
Trial: NCT00478322
Drug: INCB013739
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INCB013739 100 mg BID
Trial: NCT00676897
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin 40mg PO or NGT
Trial: NCT00676897
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corn Starch
Trial: NCT03303677
Drug: Topical Antibacterial (Product)
RxNorm normalized name: Dermoplast Antibacterial Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The antibiotic would be chosen based on intra operative culture sensitives as is our standard practice. The antibiotic would be selected from Levaquin, Vancomycin, Gentamicin, Ciprofloxacin, Mupirocin, and Trimethoprim/Sulfamethoxazole
Trial: NCT03743896
Drug: Transdermal Glucosamine Cream
RxNorm normalized name: glucosamine Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02254083
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00803166
Drug: Halobetasol Propionate 0.05% Cream-Reference Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small amount applied and evaluated over the course of three days
Trial: NCT00803166
Drug: Halobetasol Propionate 0.05% Cream-Test product 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small amount applied and evaluated over the course of three days
Trial: NCT00803166
Drug: Halobetasol Propionate 0.05% Cream-Test Product 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small amount applied and evaluated over the course of three days
Trial: NCT01129531
Drug: AGN-214868
RxNorm normalized name: VITEX AGNUS-CASTUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AGN-214868 injected into areas of postherpetic neuralgia pain for total dose per treatment.
Trial: NCT04570254
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Melatonin Tablet 5 mg. A dose of 50 mg every 24 hours. Grind the 10 5 mg melatonin tablets (50 mg), levitate with 50 mL of Ora-plus (Transferring to a beaker with a magnetic stirrer). Maintain gentle agitation. Rinse the mortar with 10 mL of Ora-sweet. Add 30 mL of Ora sweet to the glass where the mixture is being made. Makeup with Ora-sweet cbp 100 mL Place label FL02 with legend Melatonin 50 mg / 20 mL. Protected from light (Dispense in a black bag that covers the transparent bag of the preparation)'s primary packaging) Give after breakfast.
Trial: NCT00553605
Drug: Ketoprofen 100mg
RxNorm normalized name: KETOPROFEN 100MG CAP,SA
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketoprofen 100 mg diluted in 100 ml of normal sodium chloride solution into the established patient's IV line by slow injection in a 20-minute period; and IV dose of 2 ml of normal sodium chloride solution as placebo for Parecoxib by bolus injection
Trial: NCT02604485
Drug: Cohort 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XOMA 358 single dose level A administered by an intravenous infusion
Trial: NCT02604485
Drug: Cohort 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XOMA 358 single dose level B administered by an intravenous infusion
Trial: NCT02604485
Drug: Cohort 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XOMA 358 single dose level C administered by an intravenous infusion
Trial: NCT02604485
Drug: Cohort 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XOMA 358 single dose level D administered by an intravenous infusion
Trial: NCT02931890
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral capecitabine in arm 1 and 2
Trial: NCT04169919
Drug: Normal Saline Flush
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline eye wash
Trial: NCT00694733
Drug: Placebo injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline injection IM monthly for 4 months
Trial: NCT00694733
Drug: Depo Lupron/Aromatase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Depo Lupron injection 7.5mg IM monthly for 8 months, with addition of testosterone gel and aromatase inhibitor months 4-8.
Trial: NCT00694733
Drug: Depo Lupron/placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Depo Lupron injection 7.5mg IM monthly for 8 months, with addition of testosterone gel and placebo months 4-8.
Trial: NCT00694733
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Cream 1ml applied twice daily for four months
Trial: NCT00647634
Drug: Xanax XR® Tablets (3 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3mg, single dose fasting
Trial: NCT00059228
Drug: 17beta Estradiol
RxNorm normalized name: Estradiol-17beta
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alora 100 microgram per day by skin patch for 6 weeks.
Trial: NCT00059228
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo skin patch for 6 weeks
Trial: NCT00619983
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 4: Will receive placebo pills
Trial: NCT00374088
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D5W bolus prior to surgery and D5W infusion after surgery in an equal volume to the drug arm.
Trial: NCT02794714
Drug: Deep neuromuscular blockade
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep neuromuscular blockade attained during surgery using Rocuronium 0.6mg/kg at induction of anesthesia with intermittent boluses of 0.15 - 0.2 mg/kg to maintain a Post Tetanic Count (PTC) of 1-2 throughout surgery. Neuromuscular blockade reversed at the end of surgery with Sugammadex 4mg/kg.
Trial: NCT02794714
Drug: Moderate neuromuscular blockade
RxNorm normalized name: Blockade
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate neuromuscular blockade attained during surgery using Rocuronium 0.6mg/kg at induction with intermittent boluses of 0.15 - 0.2 mg/kg to maintain Train of Four Count (TOFC) of 2 throughout surgery. Neuromuscular blockade reversed at the end of surgery with Sugammadex 2mg/kg.
Trial: NCT00657514
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet po bid up to 2 tablets po bid if tolerated
Trial: NCT01175564
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet, single dose and 6 days repeated dose
Trial: NCT03493568
Drug: Genvoya 150Mg-150Mg-200Mg-10Mg Tablet
RxNorm normalized name: Genvoya 150mg-150mg-200mg-10mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: switch to Genvoya 150Mg-150Mg-200Mg-10Mg Tablet in patients virologically suppressed HIV-1 infected patients.
Trial: NCT03544229
Drug: TAK-906 Maleate
RxNorm normalized name: maleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-906 maleate capsules.
Trial: NCT03544229
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-906 maleate placebo-matching capsules.
Trial: NCT02427841
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03187353
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo capsule will be filled with microcellulose.
Trial: NCT02414347
Drug: F 18 T807
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
Trial: NCT03919409
Drug: TS-161
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TS-161 capsules
Trial: NCT03919409
Drug: TS-161 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TS-161 matching placebo capsules
Trial: NCT00376012
Drug: Anti-TB drugs (Ethambutol, Isoniazid, Rifampicin and Pyrazinamide)
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm 1 is a standard six-month intermittent regimen consisting of Ethambutol, Isoniazid, Rifampicin and Pyrazinamide given thrice weekly for 2 months followed by Rifampicin and Isoniazid given thrice-weekly for 4 months.
Trial: NCT00376012
Drug: Anti-TB drugs (Ethambutol, Isoniazid, Rifampicin and Pyrazinamide)
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm 1 is a standard six-month intermittent regimen consisting of Ethambutol, Isoniazid, Rifampicin and Pyrazinamide given thrice weekly for 2 months followed by Rifampicin and Isoniazid given thrice-weekly for 7 months.
Trial: NCT01547520
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 ml of normal saline, intramuscular, 5 to 10 minutes before EGD
Trial: NCT04167228
Drug: Best Available Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with complicated urinary tract infections, nosocomial pneumonia (including pneumonia associated with ventilation), complicated intra-abdominal infections or bacteremia (if the focus of infection is any of the above, the patient should be included in both groups) due to CRE, treated \> 2 days with the best available treatment other than ceftazidime-avibactam.
Trial: NCT00819403
Drug: simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive 6 weeks of simvastatin 40 mg, after which atherothrombotic biomarker assessment will be studied.
Trial: NCT00819403
Drug: ezetimibe/simvastatin
RxNorm normalized name: EZETIMIBE/SIMVASTATIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive 6 weeks of ezetimibe/simvastatin 10/40 mg, after which atherothrombotic biomarker assessment will be studied.
Trial: NCT00421226
Drug: ACZ885
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04052932
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets，QD
Trial: NCT01603342
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Following a baseline punch biopsy, all subjects will then receive oral placebo over a period of approximately 3 to 4 days. Once the subject has successfully had 3 days of clopidogrel dosing, a second biopsy will be performed
Trial: NCT00511797
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02680197
Drug: CHF5259 or Placebo administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of 2 puffs of treatment in the morning and in the evening during a 4 week period. Each patient will be allocated to 3 out of the 5 possible treatments.
Trial: NCT01492621
Drug: Desvenlafaxine
RxNorm normalized name: Desvenlafaxine
DrugBank: Desvenlafaxine (DB06700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desvenlafaxine 50mg from week 1-8. At week 8 optional increase to 100mg if remission has not been attained.
Trial: NCT02238106
Drug: Serevent® Diskus®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02238106
Drug: Placebo HandiHaler®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02238106
Drug: Placebo Diskus®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01891890
Drug: Oxcarbazepine
RxNorm normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Titration to target dose starting at week 3. Dose increments above target may be made to a maximum of 3 increments with a minimum interval between dose escalations of 2 weeks.
Trial: NCT00365560
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02670252
Drug: Cyclophosphamide (CY)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
Trial: NCT01540812
Drug: Hydrocortisone in induction
RxNorm normalized name: hydrocortisone Injection
DrugBank: Hydrocortisone acetate (DB14539)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01540812
Drug: PEG-ASP in consolidation-2
RxNorm normalized name: PEG-2 STEARATE
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02819856
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg SPI-1005 bid po x 21d
Trial: NCT01540812
Drug: PEG-ASP in consolidation-3
RxNorm normalized name: PEG-3 cocamine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02896101
Drug: Elidel® (pimecrolimus) Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01125566
Drug: BIBW 2992
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients receive BIBW 2992 tablets once daily and can reduce dose for adverse event management
Trial: NCT02725008
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: to be given to the experimental group on the day after discharge from the ED in lieu of the second dose of dexamethasone
Trial: NCT02175745
Drug: 18F-fluoro-dihydroxyphenylalanine
RxNorm normalized name: 6-Fluoro-(18F)-L-3,4-Dihydroxyphenylalanine
DrugBank: Fluorodopa (18F) (DB13848)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered intravenously (IV)
Trial: NCT00808899
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide
Trial: NCT00808899
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin
Trial: NCT03774875
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets taken orally twice a day
Trial: NCT02624375
Drug: Zoster Vaccine Live
RxNorm normalized name: zoster vaccine live
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02257918
Drug: AZD0914
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD0914 is an antimicrobial amorphous nonsterile powder. Group 1 receive 2000 mg; Group 2 receive 3000 mg. The drug name is also known as ETX0914.
Trial: NCT00135785
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02053740
Drug: Routine western medicine
RxNorm normalized name: western larch pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04440059
Drug: ICP-022
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICP-022 at a dose of 150mg PO QD
Trial: NCT00554086
Drug: Escalating dose of Casodex from 50mg daily to 150 mg daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Casodex dosage increase from 50mg to 150mg daily until baseline serum PSA is reduced by 50%
Trial: NCT00658840
Drug: Capecitabine (Xeloda®)
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine is administered orally at a dose of 800 mg/m2 twice daily (total daily dose 1600mg/ m2) continuous regimen regimen during RT (5 days of treatment followed by a 2 day rest: Saturday and Sunday). Capecitabine is given approximately 12 hours apart and taken orally with water within 30 minutes after ingestion of food (breakfast or dinner).
Trial: NCT01287845
Drug: BAY1075553
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cancer patients, single intravenous bolus injection of 300 MBq BAY1075553 over 60 seconds on the treatment day 1
Trial: NCT01287845
Drug: BAY1075553
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy volunteers for dosimetry, single intravenous bolus injection of 300 MBq BAY1075553 over 60 seconds on the treatment day 1
Trial: NCT00474383
Drug: Glucocorticoid
RxNorm normalized name: Glucocorticoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone/prednisolone 5 mg tablet orally twice daily/dexamethasone 0.5 mg tablet orally once daily continuously in 28-day cycle up to disease progression, death, or end of study.
Trial: NCT00110955
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Q3W dosing of placebo
Trial: NCT01381627
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remifentanil IV bolus 0.5 mcg/kg bolus in 10 minutes. Initial bolus followed by infusion 0.05-0.25 mcg/kg/min for OAA/S 2-3. Remifentanil IV bolus 0.3 mcg/kg PRN for time-limited painful stimuli.
Trial: NCT00174798
Drug: SSR240600C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily
Trial: NCT00174798
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT01765452
Drug: Closone
RxNorm normalized name: erythromycin estolate Oral Capsule [Ilosone]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75mg/100mg, 8weeks, PO
Trial: NCT01765452
Drug: Plavix with Astrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75mg, 100mg a day, 8weeks, PO
Trial: NCT03075241
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive or inert pill which will be used as a comparator
Trial: NCT01865500
Drug: Metil prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01138930
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo daily
Trial: NCT03606122
Drug: PD P 506 A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD P 506 A is a dermal patch of 4 cm² in size loaded with 2 mg 5-ALA (as 5-ALA HCl) per cm²